These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 6805321)

  • 21. Recommended guidelines for quality assurance in hospital centralized intravenous admixture services. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1980 May; 37(5):645-55. PubMed ID: 7386471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Droperidol stability in intravenous admixtures.
    Ray JB; Newton DW; Nye MT; Leet WA
    Am J Hosp Pharm; 1983 Jan; 40(1):94-7. PubMed ID: 6823997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Premixed intravenous admixtures: a positive development for hospital pharmacy.
    Lee HE
    Am J Hosp Pharm; 1983 Jun; 40(6):1043-4. PubMed ID: 6869393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Studies on bacteriologic contamination of potassium chloride solution 25% in multidose containers regularly used on hospital wards].
    Schramm G; Bianchi S
    Schweiz Med Wochenschr; 1982 Aug; 112(31-32):1099-100. PubMed ID: 6753141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbial contamination of antiseptics and disinfectants.
    Danchaivijitr S; Dhiraputra C; Rongrungruang Y; Srihapol N; Pumsuwan V
    J Med Assoc Thai; 2005 Dec; 88 Suppl 10():S133-9. PubMed ID: 16850658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EmulSiv filter removes microbial contamination from propofol but is not a substitute for aseptic technique.
    Hall WC; Jolly DT; Hrazdil J; Galbraith JC; Greacen M; Clanachan AS
    Can J Anaesth; 2003; 50(6):541-6. PubMed ID: 12826543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring contamination levels of in-use intravenous solutions using "total sample" techniques.
    Hanson AL; Shelley RM
    Am J Hosp Pharm; 1974 Aug; 31(8):733-5. PubMed ID: 4853252
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of an aseptic technique testing and challenge kit (ATTACK).
    Turco S; Miele WH; Barnoski D
    Hosp Pharm; 1993 Jan; 28(1):11-3, 16-8. PubMed ID: 10124004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sterile Product Packaging and Delivery Systems.
    Akers MJ
    Int J Pharm Compd; 2015; 19(6):491-500. PubMed ID: 26891564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommended methods for compounding intravenous admixtures in hospitals.
    Am J Hosp Pharm; 1975 Mar; 32(3):261-70. PubMed ID: 1136973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of microbial contamination associated with different preparation methods for neonatal intravenous fat emulsion infusion.
    Crill CM; Hak EB; Robinson LA; Helms RA
    Am J Health Syst Pharm; 2010 Jun; 67(11):914-8. PubMed ID: 20484215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Premixed intravenous admixtures: a critical challenge for hospital pharmacy.
    Loeb AJ; Fishman DA; Kochis TR
    Am J Hosp Pharm; 1983 Jun; 40(6):1041-3. PubMed ID: 6869392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential for microbial contamination of ADD-Vantage admixtures.
    Hudson TJ; Ambroziak EM; Coley RM
    J Pharm Technol; 1992; 8(5):195-7. PubMed ID: 10121013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step.
    Castagne V; Habert H; Abbara C; Rudant E; Bonhomme-Faivre L
    J Oncol Pharm Pract; 2011 Sep; 17(3):191-6. PubMed ID: 20630921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An in vitro analysis of microbial transmission during EUS-guided FNA and the utility of sterilization agents.
    Sing J; Erickson R; Fader R
    Gastrointest Endosc; 2006 Nov; 64(5):774-9. PubMed ID: 17055873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qaulity-control plan for intravenous admixture programs. II: Validation of operator technique.
    Morris BG; Avis KE; Bowles GC
    Am J Hosp Pharm; 1980 May; 37(5):668-72. PubMed ID: 7386475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of three methods for detecting bacterial contamination in intravenous solutions.
    Hoffman KH; Smith FM; Godwin HN; Hogan LC; Furtado D
    Am J Hosp Pharm; 1982 Aug; 39(8):1299-302. PubMed ID: 6751078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Particulate matter assessment of a clinical investigation on filtration and infusion phlebitis.
    Schroeder HG; DeLuca PP
    Am J Hosp Pharm; 1976 Jun; 33(6):543-6. PubMed ID: 1274972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Solving problems associated with large-volume parenterals. I: pharmacist responsibility for compounding intravenous admixtures.
    Zellmer WA
    Am J Hosp Pharm; 1975 Mar; 32(3):255. PubMed ID: 1136972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.